REAL-WORLD DATA DESCRIBING THE ROLE OF CHEMOTHERAPY IN THE TREATMENT OF HR+/HER2- MBC PATIENTS- DIVERGENCE FROM EVIDENCE-BASED MEDICINE

Author(s)

Feinberg B1, Kish J2, Dokubo I3, Wojtynek J3, Lord K4
1Cardinal Health Specialty Solutions, ATLANTA, GA, USA, 2Cardinal Health Specialty Solutions, Dublin, OH, USA, 3Athenex Inc., Schaumburg, IL, USA, 4Cardinal Health Specialty Solutions, San Antonio, TX, USA

Presentation Documents

OBJECTIVES

Randomized controlled trials and published guidelines recommend endocrine therapy, specifically cyclin-dependent kinase 4/6 inhibitors (CDK 4/6i) in combination with either aromatase inhibitors or fulvestrant, as first-line (1L) therapy for hormone receptor-positive (HR+) human epidermal receptor2 negative (HER2-) metastatic breast cancer (mBC). Chemotherapy is reserved for patients in visceral crisis. We aimed to understand the use of 1L chemotherapy in the treatment of HR+/HER2- mBC in the U.S. post-approval of the first CDK 4/6i palbociclib in 2015.

METHODS

Female HR+/HER2- patients diagnosed with mBC (at least one non-diagnostic inpatient/two outpatient claims for breast cancer and one claim for lymph node/distant metastatic disease) initiating 1L treatment between 01/01/2015 and 10/31/2018 were identified in the Symphony Health administrative claims database. Regimes received in 1L were categorized as: single-agent chemotherapy (saChemo), combination chemotherapy (cChemo), and hormonal/targeted (H/T). Patient demographics, frequency of use of agents, comorbidities (Charlson components) at 1L initiation, and the proportion of patients who had not initiated second-line (2L) therapy (proxy for progression-free survival) at 6 months from 1L start of treatment (Kaplan-Meier method) were assessed.

RESULTS

4317 HR+/HER- patients were identified. 1L treatment patterns/mean age: saChemo 18%/64yrs, cChemo 21%/61yrs, H/T 61%/67yrs. Comorbidities >2: saChem=6%, cChemo=4%, H/T=6%. Visceral metastasis: saChemo=23%, cChemo=19%, H/T=58%. The top 3 most frequent saChemo: capecitabine=12%, paclitaxel=11%, nab-paclitaxel=11%; cChemo: cyclophosphamide/doxorubicin=23%, cyclophosphamide/docetaxel=9%, carboplatin/paclitaxel=4%.; H/T: anastrozole=25%, letrozole=23%, fulvestrant=13%. 6-month proportion of patients not initiating 2L, saChemo: paclitaxel=94%, capecitabine=76%, docetaxel=60%; cChemo: carboplatin/nab-paclitaxel=86%, carboplatin/paclitaxel=84%, carboplatin/docetaxel=74%; H/T: letrozole/palbociclib=89%, letrozole=84%, anastrozole=82%.

CONCLUSIONS

Endocrine therapy is recommended by the NCCN guidelines as the treatment of choice for HR+/HER2- patients. However, chemotherapy still constitutes >40% of 1L choices since the introduction of CDK4/6i. More alarming is the continued use of cChemo for these patients. Further long term follow-up is needed to understand median time to next treatment (proxy for progression-free survival).

Conference/Value in Health Info

2019-11, ISPOR Europe 2019, Copenhagen, Denmark

Code

PCN325

Topic

Health Service Delivery & Process of Care

Topic Subcategory

Disease Management, Prescribing Behavior, Treatment Patterns and Guidelines

Disease

Drugs, Oncology

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×